Regulated activation of integrins is critical for cell adhesion, motility and tissue homeostasis. Talin and kindlins activate β1-integrins, but the counteracting inhibiting mechanisms are poorly defined. We identified SHARPIN as an important inactivator of β1-integrins in an RNAi screen. SHARPIN inhibited β1-integrin functions in human cancer cells and primary leukocytes. Fibroblasts, leukocytes and keratinocytes from SHARPIN-deficient mice exhibited increased β1-integrin activity, which was fully rescued by re-expression of SHARPIN. We found that SHARPIN directly binds to a conserved cytoplasmic region of integrin α-subunits and inhibits recruitment of talin and kindlin to the integrin. Therefore, SHARPIN inhibits the critical switching of β1-integrins from inactive to active conformations.
Integrins are heterodimeric transmembrane proteins composed of α-and β-subunits, which mediate cell-cell and cell-extracellular matrix adhesions 1 . The affinity of integrins for their ligands (integrin activation) is allosterically regulated [2] [3] [4] . Regulation of integrin activity is fundamentally important during development and in many physiological processes in adults 2,3,5-8 . It is now widely accepted that binding of the cytoplasmic proteins talins (TLN1,2) and kindlins (FERMT1-3, fermitin family member 1-3) to the cytoplasmic tail of the integrin β-subunit is critical for integrin activation 2,9 . However, molecules capable of inactivating integrins are not well characterized for the β1-integrins.
SHARPIN is a cytosolic protein with relative molecular mass of 45,000, originally identified in the postsynaptic density of excitatory synapses in brain, where it binds SHANK proteins 10 . We identified SHARPIN as a widely expressed endogenous inhibitor of β1-integrin activity.
RESULTS

An RNA interference (RNAi) screen identifies SHARPIN as an inhibitor of β1-integrin activity
To uncover proteins that function as endogenous inhibitors of β1-integrin (ITGB1) activity, we carried out a high-throughput RNAi screen in PC3 prostate cancer cells using a Qiagen kinase-phosphatase short interfering RNA (siRNA) library, targeting 897 known or putative genes encoding human kinases, phosphatases and certain other proteins. As integrin activation involves profound conformational changes, specific monoclonal antibodies can be used to detect β1-integrin activation 11 . Cells were transfected by growing them on microarrays of siRNA-containing matrix spots. Subsequently, the cells were fixed and stained with 12G10 (an active β1-integrin-conformationspecific monoclonal antibody 11 ), fluorescently labelled phalloidin (for determination of cell area) and a DNA stain (for normalization of cell numbers). Samples were then analysed using automated microscopy ( Fig. 1a,b) . Negative control siRNA and two validated siRNAs for ITGB1 (the β1-integrin gene) were used as negative and positive controls, respectively ( Supplementary Fig. S1a ). As binding of 12G10 may influence integrin conformation in live cells, it was critical to use fixed cells. Importantly, the specificity of the 12G10 antibody for β1-integrin was retained also in fixed cells, as staining was lost on β1-integrin silencing ( Supplementary Fig. S1b ).
In the screen, 44 siRNAs (2.5% hit rate) induced a significant increase in active integrin expression (Z -score greater than +2 s.d.; Fig. 1b) . Each gene was targeted by two independent siRNAs, and for five genes both siRNAs (see Supplementary Table S1 for siRNA Supplementary Fig. S5 ). (d) ScanR microscopy analysis of PC3 cells transfected as in c and stained with two β1-integrin active epitope antibodies (9EG7 and 12G10) and one total β1-integrin antibody (K20; shown in Supplementary Fig. S2a ). Shown are mean fluorescence intensities (MFIs) of 12G10 and 9EG7 relative to K20 (n = 3). Value 1.0 is assigned to control-siRNA-treated cells. (e) FACS analysis of PC3 cells transfected as indicated and stained for surface levels of active (9EG7 and 12G10) or inactive (Mab13 and 4B4) β1-integrins. Shown are representative histograms and the MFI. The MFI in the control transfected cells is set to 1.0 for each antibody, n = 4. (f) FACS analysis of 9EG7 labelling from PC3 cells double transfected with siRNAs and plasmids expressing siRNA-resistant GFP-SHARPIN or GFP alone. Shown are the MFIs, n = 3. (g) The binding of fibronectin (FN7-10 fragment) to control and SHARPIN -silenced cells was analysed using FACS. The staining intensities were normalized against total β1-integrin levels (n = 3). (h) The adhesion of PC3 cells, transfected as indicated, to fibronectin for the indicated times was scored using propidium iodide stain (n = 3). (i) Control and SHARPIN siRNA1 transfected PC3 cells adhering to the indicated concentrations of collagen I were scratch-wounded and analysed using time-lapse microscopy for 15 h. Shown are representative cell-tracks and quantitation of the migration speed (n = 100 cells). (j) Migration on plastic of PC3 cells transfected with plasmids expressing GFP or GFP-SHARPIN, n = 174 cells. All numerical data are mean±s.e.m., * P < 0.05, * * P < 0.01, * * * P < 0.001, n.s., not significant. 
SHARPIN regulates integrin activity in cancer cells
SHARPIN has been detected in brain, spleen, lungs 10 and certain cancer types 19 . We found SHARPIN to be fairly broadly expressed at different protein/messenger RNA levels in several human cancer cell types and most normal tissues ( Supplementary Fig. S1c,d) .
Endogenous SHARPIN localized to membrane ruffles, the cytosol and the nucleus, and this localization was not influenced by green fluorescent protein (GFP) or MYC tags on the proteins ( Supplementary  Fig. S1e ). Two different siRNAs against SHARPIN effectively knocked down the protein in PC3 cells (Fig. 1c) . In line with the siRNA screening results, active β1-integrin staining (12G10) was increased (24 ± 4% for siRNA1 and 19 ± 3% for SMARTpool siRNA) in cells transfected with the two different SHARPIN siRNAs (Fig. 1d) , whereas the total amount of β1-integrin, detected by K20 (ref. 11), was not altered (Supplementary Fig. S2a) . A second monoclonal antibody recognizing another epitope specific for the active conformation of β1-integrin (9EG7; ref. 11) also displayed significantly increased staining of SHARPIN -silenced cells. Conversely, overexpression of SHARPIN in PC3 cells decreased both 12G10 and 9EG7 staining (Fig. 1c,d ). Importantly, integrin activation was similar in SHARPIN -silenced cells and in cells overexpressing talin-head, a construct sufficient for integrin activation 20 ( Supplementary Fig. S2b ). Furthermore, silencing of talin reduced β1-integrin activity to a similar extent as overexpression of GFP-SHARPIN ( Supplementary Fig. S2b ).
SHARPIN silencing also induced significant changes in the levels of active and inactive β1-integrins on the cell surface as detected by flow cytometry. Silencing of SHARPIN increased 12G10 and 9EG7 and reduced Mab13 and 4B4 stainings (two monoclonal antibodies specific for inactive β1-integrin; ref. 11) but did not markedly alter total surface β1-integrin levels on the cell (Fig. 1e and Supplementary Fig. S2c,d) . Importantly, the ability of SHARPIN siRNAs to increase β1-integrin activity was specifically due to loss of SHARPIN protein rather than off-target effects, as transfection of SHARPIN -silenced cells with siRNA-resistant GFP-SHARPIN significantly decreased β1-integrin activity when compared with GFP-transfected control cells (Fig. 1f) .
Also in NCI-H460 human non-small-cell lung cancer cells, silencing of SHARPIN resulted in significant increase of β1-integrin activity as detected by increased 9EG7 and decreased Mab13 staining on the cell surface ( Supplementary Fig. S2e,f) . Taken together, these data indicate that SHARPIN functions as an inhibitor of β1-integrin activity in human cancer cell lines.
SHARPIN regulates ligand binding and migration of cells
Inside-out activation of integrins induces ligand binding, cell adhesion and migration 21 . We found that SHARPIN silencing enhanced integrin binding of Alexa647-labelled fibronectin repeat 7-10 (FN7-10; Fig. 1g ), which harbours the integrin binding RGD motif 22 . In addition, SHARPIN silencing induced cell adhesion to fibronectin (Fig. 1h) . Cell migration is dependent on matrix concentration and receptor activity (following a bell-shaped response curve) 23 . Time-lapse imaging and tracking showed that silencing of SHARPIN significantly increased the speed of cell migration only on low matrix concentrations (Fig. 1i) . Finally, reduction of integrin activity by overexpression of GFP-SHARPIN significantly decreased cell motility on plastic (Fig. 1j ), whereas transfection with two different SHARPIN siRNAs significantly increased cell motility ( Supplementary Fig. S2g ). These assays demonstrate that SHARPIN functionally inhibits ligand binding to β1-integrins and β1-integrin-mediated cellular functions, consistent with its ability to inhibit activation of β1-integrin.
SHARPIN interacts with the cytoplasmic domain of integrin α-subunits
All well-characterized regulators of integrin activity, such as the activators talins and kindlins, and integrin inhibitors, such as filamin (FLN) and docking protein 1 (DOK1), function by interaction with the integrin β-subunit 24, 25 . However, in pulldown experiments with biotinylated peptides of the cytoplasmic domains of β1, α1-(ITGA1) and α2-integrins (ITGA2; Fig. 2a ) we unexpectedly found that MYC-tagged SHARPIN bound to α1-and α2-tail peptides, but not to the β1-cytoplasmic tail (Fig. 2b) . The interaction was seen when the α-tail peptides contained the conserved membrane proximal segment found in all integrin α-subunits (α2-cons), whereas binding to the α2-tail lacking this sequence (α2-cterm) was at background levels ( Fig. 2b) . Importantly, endogenous SHARPIN also bound to the α-conserved tail but not to the β1-tail (Fig. 2c) . Thus SHARPIN associates with the cytoplasmic domain of integrin α-subunits.
Pulldown experiments with recombinant, purified glutathione S-transferase (GST)-SHARPIN and biotinylated integrin tail peptides (Fig. 2d) revealed that GST-SHARPIN bound directly to the α2-tail but not the β1-tail (the recombinant talin 1-400 fragment 26 was used as a positive control for the β1-tail pulldown). On the basis of fluorescence polarization titrations between GST-SHARPIN and the α-conserved tail, the affinity of the interaction was 26 ± 5 µM (α2 wild type; five α2-specific carboxy-terminal amino acids were included to obtain solubility and to ensure proper folding; Fig. 2e ). Alanine scanning mutations within the integrin α-tail conserved segment revealed that SHARPIN binding is mainly mediated by residues WK, LG and FF (Fig. 2e) . The conserved arginine (residue 8 of the peptide) may form an inhibitory salt bridge with the integrin β1-subunit 27 . If SHARPIN bound to this residue, it could disrupt the salt bridge and activate rather than inactivate integrins. Notably, in line with the inhibitory effect of SHARPIN on integrin activity, SHARPIN interaction with the integrin α-tail did not require arginine 8 in the peptide.
The specificity of the pulldown experiments was corroborated with further controls. GST-SHARPIN did not interact with scrambled α2-peptide (amino acids from the α2-cons peptide in random order) or mutated α2-34AA-tail or β1-tail (Fig. 2f) . In addition, the interaction between GST-SHARPIN and α2-cons was partially competed by excess non-biotin-labelled α2-cons peptide but not β1-tail peptide. Finally, in cells GFP-SHARPIN was found to co-precipitate with α2-and α5-cytoplasmic tails, but not the β1-tail, fused to the extracellular and transmembrane parts of the interleukin receptor ILR2α TAC 
SHARPIN co-localizes and interacts with β1-integrin in cells
Next we studied whether SHARPIN and integrins can also physically interact in intact cells. We found that SHARPIN localizes to the cytoplasm and membrane ruffles at the cell periphery of NCI-H460 cells (Fig. 3a) . SHARPIN was found to co-localize with inactive β1-integrin in these ruffles in non-transfected ( Fig. 3a) and control-siRNAtransfected cells (Fig. 3b, left) , whereas the ruffles were absent from the more spread SHARPIN -silenced cells (Fig. 3b, right) . In contrast, active β1-integrin predominantly localized to the substrate-facing matrix adhesions and did not co-localize with SHARPIN (Fig. 3a) . These data show that SHARPIN co-localizes with inactive β1-integrins in cells, and are consistent with its role in inactivating integrins that mediate cell adhesion to the matrix.
In co-immunoprecipitation experiments from PC3 cells grown on plastic (Fig. 3c) , SHARPIN co-precipitated strongly with α2β1-integrin and, to a lesser extent, with α5β1-integrin when monospecific anti-integrin antibodies ( Supplementary Fig. S3 ) were used for the immunoprecipitation. On plastic, cell adhesion is mediated predominantly by α5β1 binding to fibronectin whereas the collagenbinding α2β1-integrin is unoccupied and potentially more shifted to the inactive conformation. Therefore, we compared the amounts of SHARPIN that co-immunoprecipitate with α2-and α1-integrins from cells in suspension and from cells adhering to their substrate collagens (Fig. 3d,e) . SHARPIN co-immunoprecipitated more strongly with α-integrins from cells in suspension, indicating that SHARPIN (preferentially) binds unoccupied/inactive integrins. Importantly, α5-integrin wild type co-precipitated SHARPIN more effectively than α5-integrin 34AA (Fig. 3f) , in which two of the SHARPIN-binding residues were mutated into alanines (see Fig. 2e ).
We also analysed the direct interactions between co-expressed GFP-SHARPIN and α5-integrin-mCherry by fluorescence resonance energy transfer (FRET) using fluorescence lifetime imaging microscopy (FLIM; ref. 30) . Direct binding between SHARPIN and α5-integrin (FRET efficiency 7.2 ± 1.4%, n = 12) was clearly seen in analyses of FRET lifetime images and cumulative FRET efficiency data (Fig. 4a) .
Collectively, these experiments demonstrate that SHARPIN directly interacts with multiple α-subunits, preferentially in their inactive conformation, in intact cells.
SHARPIN inhibits recruitment of talin and kindlin to
β1-subunits SHARPIN could inactivate integrins by modulating the expression and/or function of the β1-integrin activators talin 3,31 or kindlin 22, [32] [33] [34] or through linear ubiquitin chain assembly complex (LUBAC)-stimulated formation of linear ubiquitin chains involved in signalling [35] [36] [37] . We found that silencing of SHARPIN did not alter protein levels of talin or kindlin (Supplementary Fig. S4a ). Furthermore, silencing of HOIP (RNF31, the catalytic subunit of LUBAC) did not induce β1-integrin activity in cells (Supplementary Fig. S4b ). To test whether binding of SHARPIN to integrin α-tails directly or indirectly inhibits binding of talin and/or kindlin to β1-integrin, we carried out two assays. First, direct binding of mCherry-talin 1 or mCherry-kindlin-2 to β1-integrin-GFP was measured using FRET-FLIM in β1-integrin-knockout mouse embryonic fibroblast (MEF) cells transfected with plasmid expressing MYC-SHARPIN or control plasmid. Comparison of FRET lifetime images and FRET efficiency data showed a very significant reduction in the interaction between β1-GFP and mCherry-talin and β1-GFP and mCherry-kindlin-2 in cells positive for MYC-SHARPIN (Fig. 4b,c) . Second, the ability of SHARPIN to influence the interaction between β1-integrin and kindlin was studied using proximity ligation assay (PLA; refs 38,39). The modest PLA signal detectable at the periphery of control cells (Fig. 4d) , indicating interaction between β1-integrin and kindlin-2, was very significantly increased in SHARPIN -silenced cells (PLA signals per cell 18±2 in control and 61±17 in SHARPIN siRNA cells (n = 274 cells, P < 0.001; Fig. 4d) .
Silencing of Sharpin in β1-null GD25 mouse cells transfected with plasmids expressing human wild-type full-length α5β1-integrin increased binding of SNAKA51 monoclonal antibody, which only detects active human α5β1-integrin 40 . In contrast, SHARPIN silencing had no effect on the low SNAKA51 labelling of transfected full-length human α5β1 legs together mutant, in which the subunits are restrained together (thus preventing inside-out activation; Fig. 4e; ref. 40) .
Together, these data suggest that endogenous SHARPIN strongly inhibits (directly or indirectly) the β1-integrin-talin and β1-integrin-kindlin interaction in cells. Therefore, the inside-out integrin activation is dynamically controlled by the balance of counteracting forces exerted by SHARPIN and talin/kindlin.
SHARPIN regulates β1-integrin activity in primary leukocytes
We then studied whether SHARPIN also regulates β1-integrin activity in non-adherent primary cells. Freshly isolated human peripheral blood leukocytes (PBL) expressed clearly detectable levels of SHARPIN PBLs were stained for α4-and α5-integrin and total β1-integrin (K20; n = 3). (e) FACS staining of cell-surface 9EG7 levels in PBL (no. 2) transfected with control or SHARPIN siRNA1 together with plasmids expressing GFP or siRNA-resistant GFP-SHARPIN. The value 1.0 was assigned to cells transfected with control siRNA and plasmid expressing GFP (n = 3). (f) FACS analysis of cell-surface levels of active (9EG7) and inactive (4B4) β1-integrin in human PBL transfected with plasmids expressing GFP or GFP-SHARPIN from three independent transfections. Binding in cells transfected with plasmids expressing GFP is assigned the value of 1.0. All numeric data are mean ± s.e.m., * P < 0.05, * * * P < 0.001, n.s., not significant. protein (Fig. 5a) . Silencing of SHARPIN in these primary cells resulted in a marked increase in β1-integrin-mediated spreading and migration on fibronectin-coated surfaces (Fig. 5b,c) without influencing cell-surface levels of α4-, α5-or β1-subunits (Fig. 5d) . In addition, SHARPIN silencing in PBL resulted in increased active β1-integrin levels on the plasma membrane when compared with control-siRNA-transfected cells. Importantly, this effect was reversed by expression of siRNA-resistant GFP-SHARPIN (Fig. 5e) . Finally, overexpression of GFP-SHARPIN in PBL resulted in a significant reduction in β1-integrin activity on the plasma membrane as detected by antibodies against active and inactive conformations of β1-integrin (Fig. 5f ). These data revealed that SHARPIN also acts as an inhibitor of β1-integrin activation in non-malignant primary cells, and controls leukocyte adhesion and migration.
SHARPIN controls β1-integrin activity in vivo
Mice harbouring a spontaneous null mutation in the Sharpin gene (C57BL/KaLawRij-Sharpin cpdm /RijSunJ, abbreviated to cpdm) display multiorgan inflammation and eosinophilic proliferative dermatitis 41, 42 . Recently, the phenotype has been associated with deregulation of NF-κB activity due to impaired linear ubiquitylation [35] [36] [37] , although mice lacking another subunit of LUBAC, HOIL-1 (RBCK1), do not have a similar phenotype 43 . We investigated whether increased integrin activity could also be detected in cells and tissues from the SHARPIN-null mice. cpdm mice had significantly higher levels (5.1 ± 0.6-fold total fluorescence intensity, n = 9 sections, P < 0.001) of active β1-integrin (9EG7 labelling) when compared with wild-type control mice (Fig. 6a) . In cpdm mice, the increased β1-activity was mainly detected in keratin 14 (KRT14)-positive keratinocytes and less in suprabasal keratinocytes positive for keratin 10 (KRT10) or involucrin (IVL; Fig. 6a ). Increased β1-integrin activity in cpdm mice was not accounted for by changes in the expression of Itgb1 or any of the Kindlin or Talin genes in the skin (Supplementary Table S2 ; microarray data published in ref. 41) .
Freshly isolated splenocytes from cpdm mice displayed 450% increased active cell surface β1-integrin (9EG7) and 200% increased fibronectin-fragment binding when compared with wild-type splenocytes (Fig. 6b) . Increased integrin activity was also detected in bonemarrow leukocytes freshly isolated from cpdm mice when compared with the corresponding wild-type cells (Fig. 6c) . These analyses show that loss of SHARPIN correlates with increased β1-integrin activity also in vivo. However, we cannot conclude that this is directly due to the loss MEFs from wild-type and cpdm mice transfected with plasmids expressing GFP or GFP-SHARPIN was analysed using FACS. The staining intensities are shown relative to wild-type MEFs transfected with plasmids expressing GFP (n = 3). Analysis of migration speed of wild-type and cpdm MEFs transfected with plasmids expressing GFP or GFP-SHARPIN (n > 25 cells).
(f) MEFs from wild-type and cpdm mice were transfected with plasmids expressing full-length α5-GFP wild type or α5-GFP 34AA mutant and the α5β1-integrin activity was analysed with SNAKA51 antibody using FACS. Shown are mean fluorescence intensities of SNAKA51 stainings relative to GFP intensity (the intensity of wild-type MEFs expressing wild-type α5 is defined as 1.0; n = 3). (g) Binding of fibronectin (FN7-10 fragment) to cpdm MEFs transfected with plasmids expressing GFP or GFP-SHARPIN in the presence or absence of membrane-permeable SHARPIN binding α-tail peptide (α1-TAT) or scramble peptide (ScrTAT) was analysed using FACS (n = 3). Control, without peptides. All numeric data are mean±s.e.m., * P < 0.05, * * P < 0.01, * * * P < 0.001, n.s., not significant.
of the integrin-inhibitory role of SHARPIN because the inflammation in the cpdm mice might influence integrins indirectly.
MEFs from wild-type and cpdm embryos (at a stage with no detectable inflammation) were analysed for FN7-10 binding. Notably, SHARPIN-null MEFs displayed 1.7-2.5-fold increased β1-integrin ligand binding with similar levels of total cell-surface β1-integrin (Fig. 6d,e) , thus demonstrating a significant increase in β1-integrin activity when compared with wild-type MEFs. The increase was specifically due to loss of SHARPIN, because re-expression of SHARPIN in the cpdm MEFs fully reversed the phenotype (Fig. 6e) . In addition, cpdm MEFs were more migratory than wild-type MEFs on plastic, which was reversed on expression of GFP-SHARPIN (Fig. 6e) .
Importantly, the ability of SHARPIN to inhibit integrin activity was found to depend on its ability to interact with the integrin α-subunit. This was shown by staining wild-type and cpdm MEFs expressing human α5-GFP wild type or α5-GFP 34AA with SNAKA51. Wild-type α5-integrin activity was 1.8 times higher in cpdm MEFs when compared with wild-type MEFs. In contrast, in cells transfected with α5-integrin 34AA, which is unable to interact with SHARPIN, SNAKA51 detected similar levels of active α5-integrin both in SHARPIN-expressing wild-type cells and SHARPIN-null cpdm cells (Fig. 6f) . In addition, a membrane-permeable soluble α-tail peptide (containing the SHARPIN binding sequence) had no effect in cpdm MEFs transfected with plasmid expressing GFP but significantly blocked the ability of GFP-SHARPIN to reduce integrin activity in cpdm MEFs, whereas a scramble control peptide had no effect (Fig. 6g) . Together these data show that loss of SHARPIN correlates with increased integrin activity in vivo and that in cells this is dependent on its ability to interact with the integrin α-subunit.
DISCUSSION
Our study demonstrates that SHARPIN inactivates integrins in many cell types and influences integrin-dependent cellular functions. It switches integrins into an inactive conformation by directly interacting with the conserved membrane proximal segment present in all integrin α-subunits. This interaction results in reduced recruitment of integrin activators talin and kindlin to the β1-subunit. In addition, loss of SHARPIN correlates with increased β1-integrin activity in vivo.
Filamin and DOK1 inhibit β1-integrin in cells by binding to the β-cytoplasmic tails and competing directly with talin binding 24, 25, 44, 45 . SHARPIN, in contrast, inhibits β1-integrin activity by binding directly to the α-subunits and its expression correlates with the low-affinity conformation of β1-integrins in vivo. We recently showed that mammary-derived growth inhibitor (MDGI) can function as a negative regulator of β1-integrins in breast cancer 46 , but overexpression or knockdown of MDGI has no detectable phenotype in vivo 47 . In contrast, SHARPIN inhibits integrin activity in many cell types, and loss of SHARPIN correlates with increased β1-activity in cpdm mice. Thus, SHARPIN can serve as a general inhibitor of β1-integrins. Identification of this function of SHARPIN opens up an interesting concept in integrin regulation by showing that the dynamic switching between inactive and active conformations 1,3,48 is physiologically controlled by a protein interacting with the α-subunits.
SHARPIN has been shown to bind to phosphatase and tensin homologue (PTEN) and inhibit its lipid phosphatase activity 49 , and to enter the nucleus and function as a transcription co-activator of the eyes absent homologue EYA-1 (ref. 50). We show here that the ability of SHARPIN to inactivate integrins is independent of these functions because SHARPIN silencing induces integrin activation in PC3 cells, which are PTEN null 51 and which also lack EYA-1 expression (Affimetric scale expression < 50; ref. 52) . In addition, our data demonstrate that SHARPIN interaction with the integrin α-tail is necessary for integrin inactivation (Fig. 6f,g ). We found that SHARPIN is not able to rescue the phenotype of cpdm MEFs in the presence of a competing soluble α-chain peptide. Furthermore, we found that the activity of a mutant α5-integrin (α5 34AA, which does not interact with SHARPIN) is not increased by deletion of SHARPIN, in contrast to the activity of wild-type α5 integrin. SHARPIN also functions as a subunit of LUBAC, which stimulates linear ubiquitin chain assembly [35] [36] [37] . However, recombinant SHARPIN (in the absence of HOIP and HOIL-1) interacts with the integrin α-tail in a ubiquitin-independent manner (as we detect binding to synthetic peptides). In addition, silencing of HOIP (the catalytic subunit of LUBAC) has no effect on integrin activity in cells (Supplementary Fig. S4b) . Moreover, about half of cellular SHARPIN is not associated with the LUBAC complex 37 . Therefore, we conclude that SHARPIN is a multifunctional molecule, which also binds directly to integrin α-subunits and inactivates integrins independently of its other functions in cells. However, these data open an intriguing further possibility whereby recruitment of LUBAC to the integrins would catalyse linear ubiquitylation of components of the adhesome and influence their function.
As early as the early 1990s it was speculated that if an association between a protein and the α-integrin GFFKR sequence occurred it might determine the default affinity state of the integrin. This hypothesis was based on a finding that deletion of the integrin α-tail before this sequence results in a constitutively active integrin 53 . We now present evidence that SHARPIN functions as such a protein in many different cell types.
In conclusion, SHARPIN is an endogenous inhibitor of β1-integrins, which uniquely binds to α-integrin subunits. It can function either by holding the integrins in an inactive state (by steric hindrance of the binding of talin and kindlin or by stabilizing the salt bridge) or by serving as an adaptor recruiting inhibitory kinase(s) to the proximity of β-chains. In any case, SHARPIN prevents interaction of β1-integrin with talin and kindlin. SHARPIN controls β1-integrin-dependent cell adhesion and migration in several normal and malignant cell types and loss of SHARPIN correlates with increased integrin activity in mice in vivo. 
METHODS
Methods
METHODS
Cell spot microarrays. For the siRNA cell spot microarrays a library with two individual siRNAs for 897 human kinases and phosphatases and certain other genes (Qiagen kin-phos library v1.0), ITGB1 (SI00300573, SI02662044) and negative control siRNAs (AllStars negative control, Qiagen 1027280, siGFP, Qiagen 1022064) were printed on a SBS-sized untreated polystyrene microplate (Nunc) using a Genetix Qarray2 (Genetix) microarray printer with 200 µm solid tip pins (PointTechnologies) as described earlier 54 . PC3 cells were transfected on the arrays for 48 h, fixed with 2% paraformaldehyde, permeabilized with 0.3% Triton-X100 in PBS and stained with an antibody specific for active β1-integrin (clone 12G10, 1:100), Alexa555-conjugated phalloidin (Invitrogen, 1:50) and DAPI. Alexa488-conjugated goat anti-mouse secondary antibody was used (1:300) to detect the primary antibody. Analysis of the arrays was carried out with an automated high-throughput fluorescence microscope (ScanR, Olympus) using a ×20 objective. Automated image analysis (ScanR, Olympus) was used to measure a cumulative F-actin segmented whole-cell area, anti-12G10 signal intensity and nuclear DNA counterstaining of all cells in each spot. The raw signal intensities were spatially centred using pin normalization and the ratio of fitted signals (12G10/DAPI) was standardized with a Z score using whole-array mean and standard deviation.
Immunofluorescence. For FACS analysis the cells were stained with the indicated integrin antibodies (1:100) followed by fluorescently conjugated secondary antibodies (1:300), as described 46 . For analysis of the binding of labelled fibronectin repeat 7-10 (ref. 22) , non-fixed cells suspended in Tyrodes buffer (10 mM HEPESNaOH at pH 7.5, 137 mM NaCl, 2.68 mM KCl, 0.42 mM NaH 2 PO 4 , 1.7 mM MgCl 2 , 11.9 mM NaHCO 3 , 5 mM glucose) were incubated with the ligand (25 µg ml −1 ) for 30 min at room temperature, washed three times with cold Tyrodes and analysed by FACS. Immunofluorescence experiments were carried out as described 39 . For analysis of integrin activity in the 96-well plates the transfected cells were fixed, permeabilized and stained for active integrins (9EG7 and 12G10, both 1:100) or total integrin (K20 or P5D2, both 1:100) and DAPI, followed by fluorescently conjugated secondary antibodies (1:300). Samples were imaged using a ScanR microscope (Olympus) and a ×20 objective and quantitated using ScanR imageanalysis software.
Dorsal skin samples from six-week-old wild-type and C57BL/KaLawRijSharpin cpdm /RijSunJ mice were embedded in optimum cutting temperature (OCT) compound, frozen, sectioned, fixed with 2% paraformaldehyde and stained with the indicated primary antibodies (1:100) and DAPI, followed by fluorescently conjugated secondary antibodies (1:300). Images were taken with a Zeiss LSM710 spinning-disc confocal microscope (CarlZeiss) and a ×20 objective.
Cell adhesion and migration assays. For migration assays subconfluent cells or cells at the edge of a scratch-wound were imaged at 10 min intervals in 10% fetal bovine serum (FBS)-containing medium on 0.1, 5 or 50 µg ml −1 collagen-coated wells (PC3) or tissue-culture plates (MEFs) for 16 h, or on 5 µg ml −1 fibronectincoated wells at 1 min intervals for 30 min (PBL). Phase-contrast images were taken with a Zeiss inverted wide-field microscope (×10 objective) equipped with a heated chamber (37 • C) and CO 2 controller (4.8%). Image processing was done with NIH ImageJ software. Migration was analysed by measuring the migration speed and path length. 
Figure S2 Regulation of β1-integrin activity by Talin-1 and SHARPIN. (a) ScanR microscopy analysis of PC3 cells transfected as in (Fig. 1c) and stained for total β1-integrin (K20). Shown are the total β1-integrin levels. 
